Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04617847) tested a medicine called WVE-120101 across different doses — 4 mg, 16 mg, and 32 mg. A total of 27 people started the trial (3 in the 4 mg group and 24 in the 16 mg group). Some participants later had their dose adjusted upward during the study. No participants were recorded as having completed the trial in the formal sense, and all were listed under "not completed," though this may reflect how the trial was structured or ended rather than dropouts alone. The reported data shows that the primary focus of this trial was on tracking adverse events — that is, unwanted medical occurrences that happened during treatment. In the 4 mg group, 2 out of 3 participants experienced a treatment-related adverse event, with none classified as severe or serious. In the 16 mg group, 17 out of 24 participants experienced a treatment-related adverse event, with 5 of those classified as severe and 3 classified as serious; 1 person in this group withdrew from the trial due to such an event. In the 32 mg group (which included participants who had their dose increased), 2 out of a small number experienced a treatment-related adverse event, with 1 classified as serious and none classified as severe; no one in this group withdrew due to an adverse event. The reported data shows only these adverse event counts — no other outcome measures, such as measures of how the disease responded, were included in the submitted results. The size of the 32 mg group was not clearly stated in the data as submitted, so a precise participant count for that group cannot be confirmed here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Huntington's Disease Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have already completed the earlier Phase 1b/2a study using the drug WVE-120101 (also known as study WVE-HDSNP1-001).
Who may not be able to join:
- You have taken another experimental drug (other than WVE-120101) within the past year, or within a certain time period based on how long that drug stays in the body — whichever is longer.
- You are unable to have a brain MRI scan, even with the help of sedation (medication to help you relax or sleep during the scan).
- You have a significant health condition found during a physical exam that is unrelated to Huntington's disease, which the study doctor believes would make it unsafe or difficult for you to complete the study (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, MD, Wave Life Sciences
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Safety: Number of Patients With Treatment-emergent AEs (TEAEs); Safety: Number of Patients With a Severe TEAE; Safety: Number of Patients With Serious TEAEs; Safety and Tolerability: Number of Patients Who Withdraw Due to TEAEs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.